Company: NCEL
Filing Date: 2025-07-18
Form Type: 6-K
Source: 0001213900-25-065657
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: 6-K
Chunk 3
---
2025. Other information
regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or
otherwise, are contained in the F-4 Registration Statement and other relevant materials to be filed with the SEC regarding the proposed
transaction when such materials become available. Investors should read the proxy statement/prospectus carefully when it becomes available
before making any voting or investment decisions. You may obtain free copies of these documents from the Company using the sources indicated
above.

<div align='center'>2

EXHIBIT INDEX</div>

<div align='center'>3

SIGNATURES</div>

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

| Date: July 18, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:--------------------|:-----------------------|:--------------------|:------------------------|
|                     |                        | Name:               | Alexander Zwyer         |
|                     |                        | Title:              | Chief Executive Officer |

<div align='center'>4</div>